Bifidobacterium animalis is a Gram-positive, anaerobic, rod-shaped bacterium of the Bifidobacterium genus which can be found in the large intestines of most mammals, including humans.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBST-054FG |
|
Product Information | |
---|---|
Product Overview | Bifidobacterium animalis is a Gram-positive, anaerobic, rod-shaped bacterium of the Bifidobacterium genus which can be found in the large intestines of most mammals, including humans. |
Target | Bifidobacterium |
Genus | Bifidobacterium |
Strain Designation | ZBM30 |
Application | Study and research |
Type Strain | No |
Culture Medium | BBL |
Culture Conditions | 37°C; Anaerobic |
Characteristics | The cells are highly variable rods, Gram-positive, without motility, no buds, strictly anaerobic. It can ferment lactose, fructose, galactose to produce acid, does not use sorbitol, it needs organic nitrogen as a nitrogen source, it also needs vitamins to grow. Oxidase and catalase were negative. Gelatin liquefaction was negative. |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They are originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status. |
Alternative Names | Bifidobacterium animalis |
Bifidobacterium animalis is widely recognized for its probiotic properties, including enhancing gastrointestinal health and supporting immune function. Research indicates that it can improve bowel function, protect against diarrhea, and reduce side effects of antibiotics, such as antibiotic-associated diarrhea.
Bifidobacterium animalis cultures should be stored at -80°C for long-term preservation. For short-term use, storing at 4°C is sufficient, but it is crucial to avoid repeated freeze-thaw cycles to maintain cell viability and probiotic effectiveness.
Bifidobacterium animalis grows best under anaerobic conditions at a temperature of around 37°C. It requires a medium that supports the growth of anaerobic bacteria, often supplemented with reducing agents like l-cysteine to enhance aerotolerance.
For animal studies, Bifidobacterium animalis can be administered orally via gavage or incorporated into the diet. It is important to standardize the dose and ensure the delivery method maintains cell viability. Typical doses range from 10^7 to 10^9 CFU per day, depending on the study's design and objectives.
In vitro assessment of probiotic efficacy includes evaluating acid and bile tolerance, adhesion to intestinal cell lines, and antimicrobial activity against pathogens. These assays help determine the strain's potential health benefits and suitability for further in vivo studies.
The survivability of infected mice is closely associated with the enrichment of several bacterial species
The study investigates the role of the gut microbiota in protecting against influenza infection, focusing on specific bacteria like Bifidobacterium animalis. Using a mouse model infected with the H7N9 virus, the research demonstrates that the gut microbiota from mice that survived infection can confer resistance when transferred to antibiotic-treated mice. Metagenomic sequencing revealed that B. animalis levels significantly increase in surviving mice. Oral administration of B. animalis alone or combined with B. pseudolongum significantly reduces the severity of infection. Functional metagenomic analysis suggests that B. animalis mediates its protective effect through specific metabolic molecules, including valine and coenzyme A, which are confirmed in vivo to have anti-influenza properties.
The study's findings highlight the importance of gut microbiota in modulating host resistance to influenza and suggest potential therapeutic uses for Bifidobacterium species in preventing and predicting influenza severity. The results show that increasing the abundance of endogenous B. animalis can enhance host resistance, representing a novel interaction between host and gut microbiota.
Zhang, Qiang, et al. "Influenza infection elicits an expansion of gut population of endogenous Bifidobacterium animalis which protects mice against infection." Genome biology 21 (2020): 1-26.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.